Molecular Research on Polycystic Ovary Syndrome (PCOS)

Daniele, Simona; Chelucci, Elisa; Scarfò, Giorgia; Artini, Paolo Giovanni

doi:10.3390/biomedicines11051358

Cited by 2 publications

(2 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The clinical necessity for robust and precise genetic biomarkers, both in tissue and blood specimens, has intensified. These biomarkers hold the promise of unraveling the complex molecular mechanism of PCOS and enhancing diagnostic accuracy ( 2 , 3 ), hence providing important support for clinical translational research initiatives ( 4 , 5 ). Noncoding RNAs are being recognized as crucial regulators of gene expression, organizing complex molecular networks that are essential to the pathophysiology of numerous diseases ( 6 - 9 ).…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Unveiling Key Biomarkers and Therapeutic Drugs in Polycystic Ovary Syndrome (PCOS) Through Pathway Enrichment Analysis and Hub Gene-miRNA Networks

Heidarzadehpilehrood,

Pirhoushiaran,

Binti Osman

et al. 2023

Iran J Pharm Res

View full text Add to dashboard Cite

Background: Polycystic ovary syndrome (PCOS) affects women of reproductive age globally with an incidence rate of 5% - 26%. Growing evidence reports important roles for microRNAs (miRNAs) in the pathophysiology of granulosa cells (GCs) in PCOS. Objectives: The objectives of this study were to identify the top differentially expressed miRNAs (DE-miRNAs) and their corresponding targets in hub gene-miRNA networks, as well as identify novel DE-miRNAs by analyzing three distinct microarray datasets. Additionally, functional enrichment analysis was performed using bioinformatics approaches. Finally, interactions between the 5 top-ranked hub genes and drugs were investigated. Methods: Using bioinformatics approaches, three GC profiles from the gene expression omnibus (GEO), namely gene expression omnibus series (GSE)-34526, GSE114419, and GSE137684, were analyzed. Targets of the top DE-miRNAs were predicted using the multiMiR R package, and only miRNAs with validated results were retrieved. Genes that were common between the ''DE-miRNA prediction results'' and the ''existing tissue DE-mRNAs'' were designated as differentially expressed genes (DEGs). Gene ontology (GO) and pathway enrichment analyses were implemented for DEGs. In order to identify hub genes and hub DE-miRNAs, the protein-protein interaction (PPI) network and miRNA-mRNA interaction network were constructed using Cytoscape software. The drug-gene interaction database (DGIdb) database was utilized to identify interactions between the top-ranked hub genes and drugs. Results: Out of the top 20 DE-miRNAs that were retrieved from the GSE114419 and GSE34526 microarray datasets, only 13 of them had "validated results" through the multiMiR prediction method. Among the 13 DE-miRNAs investigated, only 5, namely hsa-miR-8085, hsa-miR-548w, hsa-miR-612, hsa-miR-1470, and hsa-miR-644a, demonstrated interactions with the 10 hub genes in the hub gene-miRNA networks in our study. Except for hsa-miR-612, the other 4 DE-miRNAs, including hsa-miR-8085, hsa-miR-548w, hsa-miR-1470, and hsa-miR-644a, are novel and had not been reported in PCOS pathogenesis before. Also, GO and pathway enrichment analyses identified ''pathogenic E. coli infection'' in the Kyoto encyclopedia of genes and genomes (KEGG) and ''regulation of Rac1 activity'' in FunRich as the top pathways. The drug-hub gene interaction network identified ACTB, JUN, PTEN, KRAS, and MAPK1 as potential targets to treat PCOS with therapeutic drugs. Conclusions: The findings from this study might assist researchers in uncovering new biomarkers and potential therapeutic drug targets in PCOS treatment.

show abstract

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Unveiling Key Biomarkers and Therapeutic Drugs in Polycystic Ovary Syndrome (PCOS) Through Pathway Enrichment Analysis and Hub Gene-miRNA Networks

Heidarzadehpilehrood,

Pirhoushiaran,

Binti Osman

et al. 2023

Iran J Pharm Res

View full text Add to dashboard Cite

show abstract

Polycystic Ovarian Syndrome: Effect of Hormones, Associated Comorbidities and Recent Advances in Therapy

Raju,

Archana,

Reddy

et al. 2024

International Journal of Innovative Science and Research Techno

View full text Add to dashboard Cite

This study addresses the prevalent endocrine disorder, Polycystic Ovarian Syndrome (PCOS), affecting women of reproductive age. The research aims to explore the epidemiology, etiology, genetic factors, transmission patterns, environmental influences, hormonal imbalances, and comorbidities associated with PCOS. The methodology involves a comprehensive review of literature, including studies on PCOS prevalence, diagnostic criteria, phenotype classification, neuroendocrine links, genetic markers, environmental and lifestyle factors, heavy metal exposure, oxidative stress, follicular ER stress, hormonal imbalances, gut hormones, and adipose tissue dysfunction in PCOS. Results point to PCOS having a multigenetic basis, being transmitted across generations, and being influenced by environmental variables. Hormonal imbalances, including androgen excess, insulin resistance, and dysregulation of gonadotropin hormones, are significant in PCOS pathophysiology. The study also discusses the impact of PCOS on infertility, psychological stress, thyroid dysfunction, insulin resistance, dyslipidemia, diabetes,and obesity. The implications of this research highlight the need for a comprehensive strategy to managing PCOS, considering genetic predispositions, environmental exposures, lifestyle modifications, and hormonal imbalances. It also discussed alternative therapies. such as yoga, tai chi, qigong, acupuncture, and Chinese herbal medicine, and discusses the current treatment options for PCOS, including meditative stress reduction, melatonin, and cryptotanshinone.

show abstract

Molecular Research on Polycystic Ovary Syndrome (PCOS)

Abstract: Polycystic ovary syndrome (PCOS) is an endocrine systemic disorder with a prevalence of between 5% and 20% that commonly affects childbearing-aged women [...]

Cited by 2 publications

References 19 publications

Unveiling Key Biomarkers and Therapeutic Drugs in Polycystic Ovary Syndrome (PCOS) Through Pathway Enrichment Analysis and Hub Gene-miRNA Networks

Unveiling Key Biomarkers and Therapeutic Drugs in Polycystic Ovary Syndrome (PCOS) Through Pathway Enrichment Analysis and Hub Gene-miRNA Networks

Polycystic Ovarian Syndrome: Effect of Hormones, Associated Comorbidities and Recent Advances in Therapy

Contact Info

Product

Resources

About